As GSK-3β is a positive regulator of NF-κB activity (Ougolkov et al, 2005, 2007), inhibition of GSK-3 may sensitise renal cancer cells to conventional chemotherapeutic agents. This evidence concerns the gene GSK3B and renal carcinoma.